GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2007

MGI Obtains Rights to Thrombocytopenia Treatment for $45M

  • MGI Pharma obtained the rights to develop AkaRx’ antithrombotic agent as well as the option to acquire the company for $45 million.

    MGI may acquire all of AkaRx’s capital stock any time prior to January 8, 2010. If the company does exercise its option, MGI will make additional payments of approximately $255 million at that time.

    The development and license agreement is related to AKR-501, and no additional milestone or royalty fees are associated with the transaction. MGI will assume responsibility for certain development activities during the option period.
    AKR-501 is an orally available small molecule thrombopoietin mimetic being developed for the treatment of thrombocytopenia. It is a full agonist that targets the c-Mpl receptor on platelet-producing cells to stimulate platelet production.

    MGI also obtained rights to AKR-201, a metabolite of thyroid hormone targeting thyroid cancer. The compound is in preclinical development and has received an orphan drug designation.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?